No increased risk for stroke in ranibizumab patients

Researchers recently examined patient records to see if there was any link between an increased risk of stroke or acute myocardial infarction (AMI) and the use of ranibizumab (Lucentis) in patients being treated for exudative age-related macular degeneration (AMD).

Data from patients over the age of 45 who were receiving ranibizumab injections was examined by researchers. The patient information was taken from the Korean National Health Insurance database. 

Researchers determined that ranibizumab intravitreal injections did not increase the overall risk of stroke or AMI. High-risk patients, however, should still be monitored.